Table 1.
Baseline characteristics of participants by treatment group.
| Probiotic | Placebo | |
|---|---|---|
| (n = 30) | (n = 30) | |
| Female | 13 (43%) | 19 (63%) |
| Male | 17 (57%) | 11 (37%) |
| Age (years) | 61.4 ± 8.9 | 56.1 ± 12.3 |
| Prediabetes | 17 | 19 |
| T2DM | 13 | 11 |
| Metformin | 14 (47%) | 14 (47%) |
| Lipid-lowering medication a | 15 (50%) | 8 (27%) |
| BP-lowering medication b | 13 (43%) | 14 (47%) |
| Height (m) | 1.7 ± 0.1 | 1.7 ± 0.1 |
| Body weight (kg) | 100.1 ± 20.4 | 101.7 ± 21.9 |
| BMI (kg/m2) | 35.5 ± 6.2 | 36.3 ± 7.5 |
Results are mean ± SD or number and percentage where appropriate. BP: blood pressure. a Statins and ezetimibe. b ACE inhibitors, angiotensin II receptor blockers, beta-blockers, and calcium channel blockers.